Nexsen Limited (ASX:NXN) sets parallel pathway to early revenue and U.S. submission for StrepSure®

Nexsen Managing Director Mark Muzzin spoke with MarketOpen to further discuss the company’s global rollout strategy for StrepSure®, following confirmation of its U.S. 510(k) regulatory pathway and a targeted Q4 2026 submission.

The update outlines a structured execution plan spanning clinical data generation, regulatory progression, manufacturing readiness and early market entry across Asia-Pacific and emerging markets.

With clinical, regulatory, manufacturing and commercial workstreams progressing in parallel, the company is positioning toward initial commercialisation while advancing its primary U.S. pathway and sequencing reflects a focus on progressing validation activities and maintaining visibility over near term operational and regulatory milestones.

With the 510(k) pathway confirmed, what are the remaining steps to Q4 2026 submission and where is execution risk highest?

With the 510(k) pathway now confirmed, our focus is on executing a defined sequence of clinical, regulatory and operational activities ahead of a targeted Q4 2026 submission. We have aligned with the FDA on our regulatory strategy, intended use, and analytical and clinical validation approach, which provides clarity on the remaining steps to submission . The immediate priorities include progressing clinical data collection, with ongoing work at Northern Health in Melbourne and the planned onboarding of U.S. clinical sites supported by a contract research organisation.

In parallel, we are advancing our Quality Management System, with external audits scheduled in Q2 2026 and ISO 13485 certification anticipated in early Q3 2026, which supports regulatory compliance requirements. Execution risk at this stage is centred on the coordination and timely delivery of these parallel workstreams, including clinical site activation, data generation and progression through defined regulatory steps.

How does early market entry in Asia-Pacific and emerging markets de-risk the U.S. pathway and support near-term revenue?

Our strategy is to pursue early market entry across Asia-Pacific and emerging markets in parallel with the U.S. pathway, enabling us to progress local validation and registration activities while advancing toward FDA submission. These markets are prioritised based on clear regulatory pathways, established clinical networks and the ability to generate early validation and commercial traction .

In regions such as Hong Kong, the rollout involves local clinical validation through hospital partnerships followed by early adoption within the healthcare system, which is expected to support initial revenue generation and provide real world validation in a clinical setting . This staged approach allows us to initiate commercial activities, build real world data and scale distribution ahead of, and alongside, our primary U.S. market entry.

What does the combined Australian and U.S. clinical dataset enable for approval and adoption, and what does it not yet prove?

Our clinical strategy incorporates data from both Australia and the United States, with the FDA confirming our proposal to include Australian data alongside two U.S. sites as part of the submission package. This enables us to generate a broader dataset across multiple clinical environments, supporting the analytical and clinical validation required for regulatory submission.

From an adoption perspective, this approach allows us to generate data in real clinical settings and support early engagement with healthcare providers. At the same time, this dataset supports the regulatory submission process rather than representing regulatory approval or established commercial adoption. Broader uptake remains dependent on completion of regulatory requirements and progression through market specific validation and registration pathways.

How does the alignment of QMS, certification, and manufacturing support initial supply, and what risks remain before rollout?

Our approach has been to align quality, certification and manufacturing activities so that regulatory compliance and supply readiness progress together. We have implemented our Quality Management System, with external audits scheduled in Q2 2026 and ISO 13485 certification anticipated in early Q3 2026, which underpins our ability to supply devices commercially across multiple jurisdictions .

Our facility at the RMIT Sir Ian Potter Nanobiosensing Facility is intended to support initial production and early demand, with capacity of approximately 1 million devices per annum . In parallel, we have established Nexsen Hong Kong Limited, which is planned to become our long term global manufacturing and distribution hub supporting large scale production and global supply .

Execution pathway supports staged commercialisation and broader platform rollout

Taken together, the strategy reflects a structured progression for Nexsen toward initial commercialisation, with clinical, regulatory and commercial workstreams advancing across multiple regions. Early market entry activities are designed to support validation and initial revenue opportunities, while the U.S. pathway progresses toward submission.

With manufacturing capability and quality systems advancing in parallel, the company is positioning to support initial supply ahead of broader scale. Over the coming months, delivery against operational, regulatory and commercial milestones is expected to define the next phase of execution as Nexsen advances its rollout strategy.